» Articles » PMID: 36460813

Micronome Revealed MiR-205-5p As Key Regulator of VEGFA During Cancer Related Angiogenesis in Hepatocellular Carcinoma

Overview
Journal Mol Biotechnol
Publisher Springer
Date 2022 Dec 2
PMID 36460813
Authors
Affiliations
Soon will be listed here.
Abstract

The high ratio of global mortality rate to incidence rate and steep increase in incidence of liver cancer warrants need for advancement of innovative cancer treatment and therapy for hepatocellular carcinoma (HCC). miRNAs are fascinating prospects as treatments in the form of miRNA mimics or therapeutic targets because of their capacity to target various mRNAs that are changed in diseased states. Micronome is a tool to find signature miRNA for any disease and there is hardly any study on micronome in HCC. The aim of the present study was to identify the genes involved in tumor growth and angiogenesis in HCC patients and determine the signature miRNA by constructing a micronome. Herein, we performed a comprehensive analysis on dysregulated genes obtained from liver cancer gene databases. Only experimentally validated miRNA of angiogenesis genes were included in the study. Micronome was constructed using Cytoscape software and search tools for the retrieval of interacting genes (STRING) database. Dysregulated genes of HCC were integrated with miRNAs for identification of signature miRNA involved and identify genes (acting as positive or negative regulator) to elucidate the potential regulatory pathway or signaling. The study clearly reflects that hsa-mir-205-5p is the signature miRNA for positively regulating angiogenesis in HCC through VEGFA. These regulatory genes and signature miRNAs may be useful to understand the unique angiogenesis process of HCC and quick development of novel/better and cost effective molecular-targeted treatment strategies in HCC as the responsible regulatory molecules can be pinpointed with limited resources with use of bioinformatics.

Citing Articles

Integrated Device for Cancer Nucleic Acid Biomarker Detection at Body Temperature.

Chen C, Wu B, Li X, Jin Y, Zhang H, Liu B Micromachines (Basel). 2025; 16(2).

PMID: 40047709 PMC: 11857440. DOI: 10.3390/mi16020192.


Therapeutic Potential of Feline Adipose-Derived Stem Cell Exosomes in the Treatment of Feline Idiopathic Cystitis: A Characterization and Functional Analysis of miRNA Content.

Rubini A, Zanotti F, Licastro D, Calogero G, Bettini G, Piccoli C Nanotheranostics. 2025; 9(1):38-51.

PMID: 39744099 PMC: 11667565. DOI: 10.7150/ntno.99383.


m6A methyltransferase METTL14‑mediated RP1‑228H13.5 promotes the occurrence of liver cancer by targeting hsa‑miR‑205/ZIK1.

Xu J, Liu C, Qu K, Zhang J, Liu S, Meng F Oncol Rep. 2024; 51(4).

PMID: 38426536 PMC: 10926101. DOI: 10.3892/or.2024.8718.


Role of Exosomal miR-205-5p Cargo in Angiogenesis and Cell Migration.

Martinez-Santos M, Ybarra M, Oltra M, Muriach M, Romero F, Pires M Int J Mol Sci. 2024; 25(2).

PMID: 38256008 PMC: 10815498. DOI: 10.3390/ijms25020934.


A Glimmer of Hope for Patients with a T3 Transformation Zone: miRNAs Are Potential Biomarkers for Cervical Dysplasia.

Wittenborn J, Flasshove E, Kupec T, Najjari L, Stickeler E, Maurer J Diagnostics (Basel). 2023; 13(24).

PMID: 38132183 PMC: 10742976. DOI: 10.3390/diagnostics13243599.


References
1.
Rawla P, Sunkara T, Muralidharan P, Raj J . Update in global trends and aetiology of hepatocellular carcinoma. Contemp Oncol (Pozn). 2018; 22(3):141-150. PMC: 6238087. DOI: 10.5114/wo.2018.78941. View

2.
Gupta M, Qin R . Mechanism and its regulation of tumor-induced angiogenesis. World J Gastroenterol. 2003; 9(6):1144-55. PMC: 4611774. DOI: 10.3748/wjg.v9.i6.1144. View

3.
Karamysheva A . Mechanisms of angiogenesis. Biochemistry (Mosc). 2008; 73(7):751-62. DOI: 10.1134/s0006297908070031. View

4.
Kaseb A, Hanbali A, Cotant M, Hassan M, Wollner I, Philip P . Vascular endothelial growth factor in the management of hepatocellular carcinoma: a review of literature. Cancer. 2009; 115(21):4895-906. DOI: 10.1002/cncr.24537. View

5.
Rupaimoole R, Slack F . MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017; 16(3):203-222. DOI: 10.1038/nrd.2016.246. View